7/19/2023 0 Comments IdarucizumabSenta Frol, MD, PhD, University Medical Centre Ljubljana, Slovenia, discusses the evidence for the use of idarucizumab in patients who suffer an acute ischemic stroke or intracranial hemorrhage (ICH). The monoclonal antibody binds to dabigatran with high specificity, for immediate reversal of its anticoagulant effects. Idarucizumab is licensed for use in adults treated with dabigatran when rapid anticoagulation reversal is required for emergency surgery or in uncontrolled bleeding.
0 Comments
Leave a Reply. |